Ivermectin treatment of onchocerciasis.
Ivermectin is a recently developed macrocyclic lactone that has widespread antiparasitic activity. A series of clinical trials has shown that ivermectin is safe and effective in the treatment of human infection with Onchocerca volvulus. Although it is rapidly microfilaricidal, it does not cause a severe reaction as is seen with diethylcarbamazine treatment. The drug also temporarily interrupts production of microfilaria but has no known long-lasting effects on the adult worms. In patients with onchocerciasis, a single oral dose of ivermectin (150 micrograms/kg) repeated once a year leads to a marked reduction in skin microfilaria counts and ocular involvement. At this dose, ivermectin causes minimal side effects and appears to be sufficiently free of severe adverse reactions to be used on a mass scale. Its use promises to revolutionise the treatment of onchocerciasis.
Taylor
H R
HR
Dana Center for Preventive Ophthalmology, Johns Hopkins University, Baltimore, Maryland 21205.
D000818:Animals; D002986:Clinical Trials as Topic; D015169:Colony Count, Microbial; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007559:Ivermectin / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008842:Microfilariae / Q000254:growth & development; D009855:Onchocerciasis / Q000188:drug therapy* / Q000635:transmission; D013997:Time Factors
D007559:Ivermectin